Prognostic immune markers in esophageal cancer patients managed with trimodal therapy
Abstract Background Esophageal cancer (ESC) is an aggressive disease which often presents at an advanced stage. Despite trimodal therapy, 40–50% patients can develop metastatic disease by 18 months. Identification of patients at risk for metastatic spread is challenging with need for improved progno...
Saved in:
| Main Authors: | Mark K. Farrugia, Elizabeth A. Repasky, Minhui Chen, Kristopher Attwood, Kayla Catalfamo, Hanna Rosenheck, Song Yao, David M. Mattson, Sarbajit Mukherjee, Moshim Kukar, Agnieszka K. Witkiewicz, Anurag K. Singh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00262-024-03891-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study
by: Sarbajit Mukherjee, et al.
Published: (2025-04-01) -
Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy
by: Ke Zhai, et al.
Published: (2025-08-01) -
The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: A retrospective study
by: Ruotong Wang, et al.
Published: (2024-09-01) -
Eosinophilic esophagitis: literature review and original case presentation
by: V. T. Ivashkin, et al.
Published: (2012-02-01) -
Polymeric Micellar Paclitaxel Plus Cisplatin Combined With Tislelizumab as the First‐Line Treatment of Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study
by: Xiaoyou Li, et al.
Published: (2025-04-01)